Evidence map›Paper›PMID 16449511›Full record

Trial reportHeart (British Cardiac Society)2006

Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial.

E S Houslay, S J Cowell, R J Prescott, J Reid, J Burton, D B Northridge, N A Boon, D E Newby, Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Heart (British Cardiac Society), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02418884 (The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus), which is not on this map. Cited by 79 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 3 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02418884 phase4unknown statusstarted 2015, after this paper: background citation

The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus

Ran2015Enrolled122Registered outcomes3Posted comparisons0ConditionsCoronary Artery DiseaseArmsRosuvastatin
PMID 15557374PMID 17560880PMID 24112318PMID 12633805PMID 24247483PMID 12563143PMID 10673250PMID 24151757other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 3 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. The Role of Inflammation in Cardiovascular Disease.International journal of molecular sciences · 2022
    Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

E S HouslayDepartment of Cardiology, Royal Infirmary, Edinburgh, UK.
S J Cowell
R J Prescott
J Reid
J Burton
D B Northridge
N A Boon
D E Newby
Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators
Edinburgh Royal Infirmary · GBBorders General Hospital · GBUniversity of Edinburgh · GBWestern General Hospital · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

objectivesTo evaluate the effect of intensive lipid-lowering treatment on coronary artery calcification in a substudy of a trial recruiting patients with calcific aortic stenosis.

methodsIn a double blind randomised controlled trial, 102 patients with calcific aortic stenosis and coronary artery calcification were randomly assigned by the minimisation technique to atorvastatin 80 mg daily or matched placebo. Coronary artery calcification was assessed annually by helical computed tomography.

results48 patients were randomly assigned to atorvastatin and 54 to placebo with a median follow up of 24 months (interquartile range 24-30). Baseline characteristics and coronary artery calcium scores were similar in both groups. Atorvastatin reduced serum low density lipoprotein cholesterol (-53%, p < 0.001) and C reactive protein (-49%, p < 0.001) concentrations whereas there was no change with placebo (-7% and 17%, p > 0.95 for both). The rate of change in coronary artery calcification was 26%/year (0.234 (SE 0.037) log arbitrary units (AU)/year; n = 39) in the atorvastatin group and 18%/year (0.167 (SE 0.034) log AU/year; n = 49) in the placebo group, with a geometric mean difference of 7%/year (95% confidence interval -3% to 18%, p = 0.18). Serum low density lipoprotein concentrations were not correlated with the rate of progression of coronary calcification (r = 0.05, p = 0.62).

conclusionIn contrast to previous observational studies, this randomised controlled trial has shown that, despite reducing systemic inflammation and halving serum low density lipoprotein cholesterol concentrations, statin treatment does not have a major effect on the rate of progression of coronary artery calcification.

Indexed as

AdultAgedAortic Valve StenosisAtorvastatinCalcinosisCoronary Artery DiseaseDisease ProgressionDouble-Blind MethodFemaleHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPyrrolesTomography, Spiral ComputedAtorvastatinHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPyrroles

Identifiers

PMID16449511
PMCPMC1861190
OpenAlexW2101310396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.